Systemic treatment for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and innovative immunotherapy demonstrate new prom...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Manushi Aggarwal, Abeer Arain, Zhaohui Jin
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2018
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/dd85b95f2f214bc6854270b02bc26dff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dd85b95f2f214bc6854270b02bc26dff
record_format	dspace
spelling	oai:doaj.org-article:dd85b95f2f214bc6854270b02bc26dff2021-12-02T16:43:21ZSystemic treatment for hepatocellular carcinoma2095-882X10.1016/j.cdtm.2018.08.003https://doaj.org/article/dd85b95f2f214bc6854270b02bc26dff2018-09-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X18300471https://doaj.org/toc/2095-882XHepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and innovative immunotherapy demonstrate new promising therapeutic options for these patients. This review article summarizes systemic treatment options evaluated in HCC focusing on the most recently published data and ongoing studies. Keywords: Hepatocellular carcinoma, Systemic treatment, Immunotherapy, Tyrosine kinase inhibitorManushi AggarwalAbeer ArainZhaohui JinKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 4, Iss 3, Pp 148-155 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Manushi Aggarwal Abeer Arain Zhaohui Jin Systemic treatment for hepatocellular carcinoma
description	Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and innovative immunotherapy demonstrate new promising therapeutic options for these patients. This review article summarizes systemic treatment options evaluated in HCC focusing on the most recently published data and ongoing studies. Keywords: Hepatocellular carcinoma, Systemic treatment, Immunotherapy, Tyrosine kinase inhibitor
format	article
author	Manushi Aggarwal Abeer Arain Zhaohui Jin
author_facet	Manushi Aggarwal Abeer Arain Zhaohui Jin
author_sort	Manushi Aggarwal
title	Systemic treatment for hepatocellular carcinoma
title_short	Systemic treatment for hepatocellular carcinoma
title_full	Systemic treatment for hepatocellular carcinoma
title_fullStr	Systemic treatment for hepatocellular carcinoma
title_full_unstemmed	Systemic treatment for hepatocellular carcinoma
title_sort	systemic treatment for hepatocellular carcinoma
publisher	KeAi Communications Co., Ltd.
publishDate	2018
url	https://doaj.org/article/dd85b95f2f214bc6854270b02bc26dff
work_keys_str_mv	AT manushiaggarwal systemictreatmentforhepatocellularcarcinoma AT abeerarain systemictreatmentforhepatocellularcarcinoma AT zhaohuijin systemictreatmentforhepatocellularcarcinoma
_version_	1718383543627808768

Systemic treatment for hepatocellular carcinoma

Ejemplares similares